Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

@inproceedings{Iqbal2011SouthwestOG,
  title={Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer},
  author={Syma Iqbal and Bryan H. Goldman and C{\'e}cilia M. Fenoglio-preiser and Heinz-Josef Lenz and Wu Zhang and Kathleen D. Danenberg and Stephen I. Shibata and Charles David Blanke},
  booktitle={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2011}
}
BACKGROUND Lapatinib (GW572016) is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2), which are reported as overexpressed in 15%-45% of gastric cancers, making them potential targets. PATIENTS AND METHODS The primary objective of this study was to assess response rate. Secondary objectives included overall survival (OS), toxicity, and the relationship of EGFR, ErbB2, and markers of angiogenesis with clinical… CONTINUE READING
44 Citations
27 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

CALGB 80403/ECOG 1206: a randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer

  • PC Enzinger, B Burtness, D Hollis
  • J Clin Oncol
  • 2010

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)

  • C Pinto, F Di Fabio, S Siena
  • Ann Oncol
  • 2007

Similar Papers

Loading similar papers…